{"filings":[{"id":888238,"accession_number":"0001193125-26-259546","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2026-06-05T20:06:36+00:00","items":["5.07"],"status":"ready","headline":"Sight Sciences elects Burbach, Encrantz as directors; ratifies Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Gerhard Burbach received 24,961,185 votes for and 2,877,580 withheld; Staffan Encrantz 23,901,624 for and 3,937,141 withheld.","Deloitte & Touche LLP ratified as independent auditor for FY 2026 with 41,059,471 for, 7,892 against, 388,895 abstain.","Annual meeting turnout was 41,456,258 shares (76.2% of outstanding) as of record date April 8, 2026.","No other stockholder proposals were presented or acted upon at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93478,"accession_number":"0001193125-26-208959","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences Q1 revenue up 13% to $19.7M; raises FY 2026 guidance; Alcon damages $55.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $19.7M (+13% YoY); net loss $13.0M ($0.24 loss per share) vs $14.2M loss in prior year.","Interventional Dry Eye revenue $1.4M (+244% YoY, +87% QoQ); Glaucoma revenue $18.3M (+7% YoY).","FY 2026 revenue guidance raised to $83M-$89M from $82M-$88M; adj. opex reaffirmed $93M-$96M.","Final Alcon judgment: $55.4M past damages + 10% ongoing royalty for Hydrus patent infringement (subject to appeal)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":19698000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93477,"accession_number":"0001193125-26-171887","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sight Sciences wins patent case vs Alcon; awarded $55.4M damages + ongoing royalty","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Final judgment in Sight Sciences' patent infringement case against Alcon for Hydrus Microstent.","Award totals $55.4M: $34.0M past damages, $14.7M supplemental, $6.8M interest through April 17, 2026.","Ongoing royalty of 10% of Hydrus revenue through expiration of last patent.","Judgment is subject to appeal; Alcon's ex parte reexamination proceedings could affect collection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105133,"accession_number":"0001193125-26-130386","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sight Sciences secures court order preserving willful-infringement verdict against Alcon; $34M award plus royalties","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Order upholds jury finding that Alcon willfully infringed three Sight Sciences patents.","Past damages of $34M ($5.5M lost profits + $28.5M royalties) plus supplemental damages and interest.","Ongoing royalty of 10% of Hydrus revenue through November 10, 2028 (last patent expiry).","Final judgment expected in months; subject to appeal and possible USPTO reexamination impact.","Company to record $5.4M success fee to Cooley LLP, excluded from non-GAAP operating expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105132,"accession_number":"0001193125-26-091482","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences Q4 revenue $20.4M (+7% YoY); guides 2026 revenue $82-88M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $20.4M (+7% YoY); Interventional Glaucoma $19.7M (+5% YoY); Dry Eye $0.7M vs $0.3M.","Q4 net loss $4.2M ($0.08 loss per share) vs $11.8M loss in Q4 2024; full-year net loss $38.4M vs $51.5M.","Cash $92M at Dec 31, 2025; Q4 cash used only $0.4M; full-year cash used $28.4M.","FY 2026 guidance: revenue $82-88M (+6-14% YoY); Glaucoma $77-81M; Dry Eye $5-7M.","Operating expenses down 25% Q4 and 13% full-year; adjusted op ex guidance $93-96M for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105131,"accession_number":"0001193125-26-035915","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Sight Sciences amends headquarters lease, extends term to December 2028","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Second Amendment to lease extends term 26 months from Nov 1, 2026 to Dec 31, 2028.","Rent abated Nov-Dec 2026; then $44,915.45/mo through Oct 2027.","Base rent increases to $46,214.21/mo Nov 2027-Oct 2028, then $47,621.20/mo through Dec 2028.","Lessor is Deerfield Campbell, LLC; lease covers Suites 100 and 120 at 4040 Campbell Avenue, Menlo Park."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105130,"accession_number":"0001193125-26-011106","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sight Sciences reports Q4 2025 revenue up 7% YoY; FY 2025 revenue down 3% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 total revenue $20.3M-$20.4M, +7% vs Q4 2024; Surgical Glaucoma +5%, Dry Eye +130%.","Full year 2025 revenue $77.3M-$77.4M, down 3% vs 2024; Surgical Glaucoma flat, Dry Eye ~$1.6M (from $4.0M).","Cash and equivalents ~$92M; Q4 cash burn ~$0.4M, FY cash used ~$28M.","Management reiterates path to cash flow breakeven without additional equity; complete results expected March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":77363000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121386,"accession_number":"0001193125-25-269525","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences Q3 revenue $19.9M, raises FY25 guidance; promotes COO and CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Surgical Glaucoma revenue $19.7M (+6% YoY); Dry Eye revenue $0.2M (-88%) as company focuses on reimbursed access.","Net loss narrowed to $8.2M ($0.16 loss per share) from $11.1M loss in Q3 2024.","Raises FY2025 revenue guidance to $76-78M (from $72-76M); reduces adj. op. expense guidance to $90-92M.","Promoted Alison Bauerlein to COO from CFO, James Rodberg to CFO, effective Nov 5, 2025.","Board members Becker and Rogers resigned; board size reduced from 9 to 7."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":56978000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121385,"accession_number":"0001193125-25-241948","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Sight Sciences gets Medicare pricing for TearCare from Novitas and FCSO; $1,141.59 fee","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Two MACs set jurisdiction-wide pricing for CPT 0563T (TearCare) at $1,141.59, effective Jan 1, 2025.","Covers 10.4M estimated Medicare lives (~30% of FFS beneficiaries) across multiple states.","Company plans to provide updated revenue and adjusted opex guidance on Q3 2025 earnings call.","Sight Access Portal launched to assist providers with benefit verifications and prior authorizations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138040,"accession_number":"0001193125-25-225041","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sight Sciences extends interest-only period to Feb 2027, ups Tranche 3 to $25M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Interest-only period extended six months to February 1, 2027.","Tranche 3 availability increased from $15M to $25M, drawable in $5M increments subject to Hercules' sole approval.","Company paid $50,000 amendment fee plus expenses; total $65M facility unchanged.","Performance Milestone II and Interest Only Extension Conditions removed from loan agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138039,"accession_number":"0001531177-25-000007","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["2.05","5.02","7.01"],"status":"ready","headline":"Sight Sciences cuts 20% workforce; CCO departs; reaffirms FY revenue guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduces headcount by 43 (~20% of global workforce); expects cash restructuring charge of $2.7M-$3.0M in Q3 2025.","CCO Matthew Link steps down effective Aug 31; eligible for severance including 1-year base salary and vesting of 61,675 RSUs.","Reaffirms FY2025 revenue guidance of $72M-$76M; updates adjusted opex guidance to $95M-$99M from $101M-$105M.","Annualized savings of ~$11.9M from workforce reductions alone.","Creates segment-specific leadership for Surgical Glaucoma and Dry Eye; delays certain R&D spend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138038,"accession_number":"0000950170-25-105012","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences Q2 2025 revenue $19.6M (-8% YoY), raises FY25 revenue guidance to $72-76M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.9M ($0.23 loss per share) vs $12.3M loss in prior year.","Surgical Glaucoma revenue $19.2M (-5% YoY); ordering accounts hit record 1,174, up 4%.","Dry Eye revenue fell to $0.3M from $1.1M as company focuses on reimbursed TearCare access.","Adjusted operating expenses $24.4M, down 8% YoY; reaffirmed FY25 guidance of $101-105M.","Tariff exposure on China products reduced from prior estimate of $3.5-4.5M to $1.0-1.5M for FY25."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":37072000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155439,"accession_number":"0001193125-25-135930","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Sight Sciences appoints Gerhard Burbach to Board; annual meeting elects directors and ratifies auditor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gerhard F. Burbach appointed to Board and Audit Committee (appointment previously disclosed April 21, 2025).","Annual meeting held June 5, 2025 with 75.1% of shares represented; three Class I directors elected.","Directors elected: Paul Badawi (24,675,076 for), Brenda Becker (20,923,888 for), Erica Rogers (23,914,492 for).","Ratification of Deloitte & Touche as independent auditor for FY2025 passed (38,080,605 for, 26,937 against, 706,687 abstain).","No other matters were presented or voted upon at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155438,"accession_number":"0000950170-25-066935","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences Q1 revenue $17.5M (-9% YoY); reaffirms FY25 guidance $70-75M; lowers expense guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $17.5M, down 9% YoY; Surgical Glaucoma $17.1M (-6% YoY); Dry Eye $0.4M (-60% YoY).","Gross margin 86% flat YoY; net loss $14.2M ($0.28 loss per share) vs $16.3M loss in prior year.","Reaffirms FY25 revenue guidance $70-75M (decline 6-12% YoY); lowers adjusted op ex guide to $101-105M.","Tariffs on China-made products seen adding $3.5-4.5M to 2025 COGS; impact larger in H2 2025.","Launched OMNI Edge with TruSync technology at ASCRS April 2025; TearCare reimbursement not assumed in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":17508000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155437,"accession_number":"0000950170-25-056724","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences appoints medtech veteran Gary Burbach to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed as Class II director effective April 21, 2025; term expires at 2026 annual meeting.","Former CEO of Thoratec (acquired by St. Jude/Abbott); also serves on BWX Technologies and Procyrion boards.","CEO Paul Badawi highlighted Burbach's commercial and operational expertise in medtech.","Eligible for non-employee director compensation; no committee assignments yet determined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173939,"accession_number":"0000950170-25-033556","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences reports Q4 revenue $19.1M (+2% YoY); guides FY2025 revenue down 6%-12%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $19.1M (+2% YoY); Surgical Glaucoma $18.8M (+9%), Dry Eye $0.3M (down from $1.6M).","FY2024 net loss $51.5M ($1.03/shr) vs $55.5M ($1.14/shr) prior; cash used $17.8M (62% improvement YoY).","FY2025 revenue guidance $70M-$75M (6%-12% decline) citing new Medicare LCDs restricting MIGS coverage with cataract.","Adj. operating expenses FY2025 guided $105M-$107M (+4-6%); next-gen OMNI expected H1 2025.","Gross margin Q4 87% vs 85% prior; cash and equivalents $120.4M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173938,"accession_number":"0000950170-25-009820","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sight Sciences sets 2025 base salaries and bonus targets for CEO, CFO, CCO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Paul Badawi base salary raised to $659K (from $640K); target bonus 75%.","CFO Alison Bauerlein base salary raised to $473K (from $450K); target bonus 60%.","CCO Matthew Link base salary raised to $433K (from $420K); target bonus 50%.","Fiscal 2025 cash incentive tied to revenue, adjusted opex, market access, clinical/R&D, and commercial launch milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173937,"accession_number":"0000950170-25-005104","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sight Sciences prelim Q4 2024 rev $18.9-19.1M (+1% YoY); Surgical Glaucoma +9%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Surgical Glaucoma revenue $18.7-18.8M (+9% YoY at midpoint); Dry Eye rev $0.2-0.3M vs $1.6M prior year.","Full year 2024 total revenue $79.7-79.9M (-2% YoY); cash and equivalents ~$120M; $1.4M generated in Q4.","New LCDs by five Medicare contractors effective mid-November restricted MIGS coverage, impacting results.","Company plans to achieve cash flow breakeven without additional equity capital; FY 2024 cash used $18.1M down from $46.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":79866000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190917,"accession_number":"0000950170-24-135402","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["2.03","3.02"],"status":"ready","headline":"Sight Sciences draws $5M additional term loan; total borrowings reach $40M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Drawdown of $5.0 million Tranche 1(b) under existing $65M Hercules Capital facility; total term loan now $40M.","Loan matures July 1, 2028; floating rate at greater of 10.35% or prime plus 2.35%.","Exit fee of 5.95% of funded amounts due upon repayment or maturity.","Warrants issued to lenders for 2% of principal amount (approx $0.1M face value), exercisable for seven years.","Proceeds for general corporate purposes; company targets cash flow breakeven without equity raise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190916,"accession_number":"0000950170-24-123336","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences reports Q3 2024 results, COO retirement, and new leadership appointments","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Q3 2024 revenue was $20.2M, up 1% YoY; net loss narrowed to $11.1M ($0.22 per share) from $13.0M.","COO Sam Park retired effective Nov 15, 2024; received retirement package including one year base salary.","Brenton Taylor appointed EVP of Operations effective Nov 4, 2024; receives $390K base salary and $800K RSU award.","MK Raheja appointed EVP of Research and Development; previously at Johnson & Johnson Vision and Abbott Medical Optics.","Full year 2024 adjusted operating expense guidance revised down to $104M-$106M from previous $107M-$109M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190915,"accession_number":"0000950170-24-112038","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sight Sciences: Final Medicare LCDs confirm coverage for OMNI and SION procedures but impose usage limitations","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Four MACs (Palmetto GBA, CGS, NGS, WPS) published final LCDs effective Nov 17, 2024, confirming coverage for single MIGS with phaco.","Coverage continues for canaloplasty/trabeculotomy (OMNI) and goniotomy (SION) procedures.","Limitations: non-coverage for first-line mild-to-moderate glaucoma, combined MIGS with aqueous shunt, and phaco with multiple MIGS.","Sight Sciences plans to engage with MACs, CMS, and clinical societies on coverage issues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207395,"accession_number":"0000950170-24-109665","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sight Sciences: Noridian final LCD confirms Medicare coverage for OMNI/SION but restricts certain uses","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Final LCD confirms Medicare coverage for phaco/IOL with single MIGS procedure (OMNI/SION) in 16 states.","Effective date of final LCD is November 17, 2024.","Non-coverage for first-line mild-to-moderate glaucoma, same-eye aqueous shunt, or multiple MIGS with cataract.","Company plans to continue engagement with MACs, CMS, and clinical societies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207394,"accession_number":"0000950170-24-089277","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences Q2 revenue $21.4M (-9% YoY); net loss $0.25/sh; FY guidance cut to $81M-$83M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $21.4M (-9% YoY); net loss $12.3M ($0.25/sh) vs $14.8M loss in Q2 2023.","Surgical Glaucoma revenue $20.2M (-5% YoY); Dry Eye revenue $1.1M (-46% YoY).","Cash used improved to $9.1M from $12.8M in Q2 2023; cash and equivalents $118.2M.","Narrowed FY2024 revenue guidance to $81M-$83M (0-2% growth) from prior $81M-$85M; adj. op. expenses $107M-$109M.","CMS proposes device-intensive status for OMNI procedure, which could increase ASC facility fee 29% in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":40635000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224812,"accession_number":"0000950170-24-070062","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sight Sciences shareholders elect three Class III directors, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Badawi, M.D., Tamara Fountain, M.D., and Donald Zurbay elected as Class III directors to serve until 2027.","Ratification of Deloitte & Touche as independent auditor for FY 2024 approved with 37.5M votes for, 334k against.","Approximately 76.37% of outstanding shares voted at the Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224811,"accession_number":"0000950170-24-066276","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sight Sciences: Draft Medicare LCDs propose no coverage restrictions for OMNI and SION","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Five MACs published draft LCDs on MIGS not proposing specific coverage criteria for OMNI (canaloplasty+trabeculotomy) or SION (goniotomy).","These procedures would remain eligible for Medicare in states covering 62% of Sight Sciences' 2023 Surgical Glaucoma revenue.","Draft LCDs propose non-coverage when an aqueous shunt/stent is performed with a MIGS procedure in the same eye at same time.","45-day comment period; finalization within 365 days. Company plans to engage with MACs, CMS, and clinical societies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224810,"accession_number":"0000950170-24-052094","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences Q1 revenue $19.3M (+2% YoY); wins $34M jury verdict against Alcon","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $19.3M (+2% YoY); Surgical Glaucoma $18.3M (+5%), Dry Eye $1.0M (-32%).","Net loss $16.3M ($0.33/share) vs $17.1M ($0.35/share); gross margin 86% vs 84% prior year.","Jury found willful infringement by Alcon; awards $5.5M lost profits + $28.5M royalty for Hydrus Microstent.","Reaffirms FY2024 revenue guidance $81M-$85M (0-5% growth) and adjusted op ex $107M-$110M.","Cash burn reduced to $10.8M (incl. $3.2M debt restructuring costs) from $17.7M in Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":19265000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224809,"accession_number":"0001193125-24-120159","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sight Sciences wins $34M patent verdict against Alcon over Hydrus Microstent","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jury found Alcon willfully infringed three Sight Sciences patents (U.S. 8,287,482, 9,370,443, 11,389,328) related to Hydrus Microstent.","Verdict awards $34M: $5.5M lost profits + $28.5M royalties for sales from commercial launch through trial.","Verdict subject to appeal; judge may later enhance damages for willfulness.","Case filed September 2021 in U.S. District Court for Delaware; trial lasted five days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244082,"accession_number":"0000950170-24-027971","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences FY2023 revenue $81.1M (+14%); guides FY2024 $81-85M (0-5% growth)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $18.8M (-9% YoY); net loss $10.7M ($0.22/sh) vs $16.9M loss ($0.35/sh) prior year.","FY2023 net loss $55.5M ($1.14/sh) vs $86.2M loss ($1.80/sh) in 2022; cash used reduced to $46.9M from $75.7M.","Operating expenses cut 20% in Q4; non-GAAP adjusted OpEx $22.3M vs $30.6M prior year.","New $65M senior secured credit facility with Hercules Capital; initial $35M drawn to refinance existing debt.","Full-year 2024 revenue guidance $81-85M (0-5% growth); expects double-digit growth in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244081,"accession_number":"0001193125-24-022830","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sight Sciences approves FY2024 exec compensation: CEO base $640K, 90% bonus target","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Paul Badawi base salary raised to $640,000 from $610,000; target bonus opportunity 90%.","COO Sam Park base salary increased to $420,000 from $410,000; target bonus 80%.","CFO Alison Bauerlein base salary set at $450,000 (annualized from April 2023 start); target bonus 80%.","FY2024 cash incentive tied to revenue, adjusted operating expense, reimbursement milestones, clinical publications, and R&D milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244080,"accession_number":"0001193125-24-012979","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2024-01-23T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences closes $65M credit facility with Hercules Capital, draws $35M to refinance prior debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$35M funded at closing from $65M total facility; used to repay $37.7M MidCap term loan.","Interest at greater of 10.35% or prime+2.35%; exit fee 5.95% on drawn amounts; 54-month maturity.","Interest-only period of 30 months, extendable to 36 upon performance milestones; warrants for 2% of loans.","Covenants include minimum cash 85% of secured obligations and trailing revenue test; prepayment premiums up to 3%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261494,"accession_number":"0001193125-23-297713","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Sight Sciences extends headquarters lease through Oct 2026; rent partially abated","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Lease amendment extends term 26 months from Sept 1, 2024 to Oct 31, 2026 for Menlo Park HQ.","Base monthly rent: abated Sept-Oct 2024; $45,456.60 Nov 2024-Oct 2025; $46,820.30 Nov 2025-Oct 2026.","Amendment reinstates a 3-year lease extension option for the company.","Lessor is Deerfield Campbell, LLC; no other material changes to lease terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261493,"accession_number":"0001193125-23-290749","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sight Sciences reports MACs delay effective date of LCDs impacting OMNI and SION to January 29, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Five MACs delayed effective date of local coverage determinations on Micro-Invasive Glaucoma Surgery from Dec 24, 2023 to Jan 29, 2024.","LCDs identify certain procedures as investigational, including canaloplasty with trabeculotomy ab interno associated with OMNI Surgical System.","The states served by these five MACs accounted for approximately 63% of Sight Sciences' Surgical Glaucoma revenue in 2022.","Sight Sciences strongly disagrees with LCDs' characterization and is pursuing remediation, including engagement with MACs and CMS, and potential reconsideration request.","The company is still assessing potential impact on coverage for its SION Surgical Instrument technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261492,"accession_number":"0001193125-23-274612","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Five MACs classify Sight Sciences' OMNI procedures as investigational; 63% of revenue at risk","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Four new MACs (Palmetto, Celerian, NGS, Noridian) plus prior WPS LCD classify OMNI canaloplasty/trabeculotomy as investigational, effective Dec 24, 2023.","The five MACs cover states representing ~63% of Sight Sciences' 2022 Surgical Glaucoma revenue.","LCDs trigger 'Reimbursement Trigger Event' under MidCap credit agreement; monthly principal payments begin Jan 2024.","If LCDs take effect, company may breach revenue covenant in 2024, allowing lender to accelerate repayment of $35M term loan.","Company plans to engage MACs and CMS to delay or reconsider; intends to pursue reconsideration if implemented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261491,"accession_number":"0000950170-23-060293","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences Q3 revenue up 7% to $20.0M, withdraws FY 2023 guidance on LCD uncertainty","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $20.0M (+7% YoY); Surgical Glaucoma $18.4M (+8% YoY); Dry Eye $1.6M (-1% YoY).","Net loss $13.0M ($0.27 per share) vs $22.2M ($0.46) a year ago; gross margin 86.6% (vs 84.3%).","Withdraws full-year 2023 revenue and adjusted operating expense guidance due to WPS LCD uncertainty.","Implements ~10% RIF expecting $7.9M annualized savings; other cost initiatives ~$5.0M annual savings.","Appointed Matt Link as Chief Commercial Officer; GEMINI 2 study shows sustained IOP reduction at 36 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":62305000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261490,"accession_number":"0001193125-23-264196","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Sight Sciences faces Medicare coverage threat for OMNI system; 63% of Surgical Glaucoma revenue at risk","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["WPS LCD classifies OMNI procedure as investigational, effective Dec 24, 2023; WPS states ~8% of 2022 Surgical Glaucoma revenue.","Four other MACs proposed similar LCDs; combined five MACs ~63% of 2022 Surgical Glaucoma revenue.","Company evaluating FY 2023 guidance due to uncertain coverage; update on Nov 7 earnings call.","Company disputes LCD, submitted 36-month GEMINI study for publication; will pursue all remediation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261489,"accession_number":"0001193125-23-257642","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2023-10-17T23:59:59+00:00","items":["2.05","7.01"],"status":"ready","headline":"Sight Sciences cuts 10% of workforce, expects $1.3M charge, reaffirms FY2023 guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduces headcount by 25 employees (~10% of global workforce) under restructuring plan.","Expects cash restructuring charge of ~$1.3M in Q4 2023, mainly severance and benefits.","Annualized savings from workforce reductions estimated at ~$7.9M.","Reaffirms FY2023 revenue guidance of $80-82M, representing 12-15% YoY growth.","Restructuring driven by proposed Medicare local coverage determinations impacting Dry Eye segment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278711,"accession_number":"0001193125-23-238641","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Sight Sciences provides CMS comments on 2024 OPPS/ASC Payment Rule for OMNI and TearCare","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted recommendations to CMS regarding OMNI Surgical System and TearCare System technologies.","Comments address proposed 2024 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgery Center (ASC) Payment Rule.","The comments are publicly accessible at regulations.gov under docket CMS-2023-0120-3392.","No financial impact disclosed; recommendations aim to influence future payment policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278710,"accession_number":"0001193125-23-232585","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences cuts FY2023 guidance to $80-82M, cites LCD uncertainty; appoints Matt Link CCO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 guidance $19-20M; FY guidance cut to $80-82M from $89-94M (12-15% YoY growth).","Proposed LCDs by 5 of 7 MACs could classify non-implantable MIGS as investigational, affecting orders.","Matt Link appointed CCO; former NuVasive President who scaled revenue from <$100M to >$1B.","Link receives $410K base salary, 50% bonus target, $660K options, and $1.54M RSUs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278709,"accession_number":"0000950170-23-037968","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences Q2 revenue $23.5M (+36% YoY); net loss narrows to $14.8M; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $23.5M, +36% YoY; Surgical Glaucoma $21.4M (+35%), Dry Eye $2.1M (+56%).","Net loss $14.8M ($0.30/share) vs $23.8M ($0.50) prior year; operating expenses down 6%.","Gross margin 85.6% (vs 84.1% prior year); cash $154.5M; long-term debt $35.0M.","FY2023 revenue guidance reaffirmed at $89-94M (25-32% YoY growth); quarterly adjusted opex ~$30.5M.","SAHARA trial met primary signs endpoint at 6 months; Cigna covers OMNI procedures (15M lives)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":42296000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296941,"accession_number":"0000950170-23-027489","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sight Sciences annual meeting elects directors, ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Encranz received 25,200,595 FOR votes; Mazzacco received 35,458,052 FOR votes.","Ratification of Deloitte & Touche as auditor passed with 41,688,515 FOR votes.","86.1% of shares represented at the June 8, 2023 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296940,"accession_number":"0001193125-23-163895","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Sight Sciences reaffirms $89-94M 2023 revenue guidance; Palmetto proposes LCD deeming OMNI investigational","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Reaffirmed FY 2023 revenue guidance of $89-94M (25-32% YoY growth) and average quarterly adjusted opex of ~$30.5M.","Palmetto GBA published proposed LCD on June 8 classifying non-implantable MIGS (including OMNI) as investigational; open meeting July 17.","Palmetto and WPS (proposed LCD June 1) states accounted for ~23% of 2022 Surgical Glaucoma revenue.","NGS plans to publish proposed LCD on June 22 with open meeting July 13; five MACs covering 63% of revenue have discussed.","Company says even if LCDs are finalized, no material impact on 2023 revenue due to 180-day implementation period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296939,"accession_number":"0001193125-23-159898","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Sight Sciences reaffirms FY23 revenue guidance; WPS proposes limiting MIGS coverage for OMNI","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Reaffirmed FY2023 revenue guidance of $89M-$94M (25%-32% growth YoY); quarterly adjusted opex ~$30.5M.","WPS (Medicare contractor) proposed LCD classifying non-implantable MIGS as investigational; would make OMNI non-covered in 6 states.","WPS-served states (KS, NE, MO, IA, IN, MI) accounted for ~8% of Surgical Glaucoma revenue in 2022.","Company strongly disagrees, plans to present clinical evidence at WPS meeting June 14 and comment period through July 15.","Precedent: Palmetto GBA withdrew similar 2020 LCD after ophthalmic community pushback."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296938,"accession_number":"0000950170-23-018879","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sight Sciences posts investor presentation to website; no material new information disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted investor presentation dated May 8, 2023 on its investor relations website.","Presentation expected to be used in meetings with investors and analysts; no specific figures or updates included in the filing.","No earnings, guidance, or strategic changes disclosed in the filing or exhibit text provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296937,"accession_number":"0000950170-23-017868","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sight Sciences Q1 revenue up 26% to $18.8M, net loss $17.1M; reaffirms FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $18.8M (+26% YoY); Surgical Glaucoma $17.3M (+25%), Dry Eye $1.5M (+47%).","Net loss $17.1M ($0.35/share) vs $23.3M ($0.49) prior year; operating expenses decreased 2% to $33.3M.","Gross margin improved to 84% from 80% due to prior year voluntary TearCare SmartHub replacement.","Reaffirmed FY2023 revenue guidance $89-94M (25-32% growth) and ~$30.5M quarterly adjusted opex.","Completed commercial launch of Ergo-Series OMNI Surgical System; cash $167.3M, debt $35.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":18824000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296936,"accession_number":"0000950170-23-011614","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences appoints Alison Bauerlein as CFO; interim CFO Rodberg steps down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alison Bauerlein named CFO & Treasurer effective April 3, 2023, succeeding interim CFO Jim Rodberg.","Base salary $410,000, target annual bonus 50% of base; granted option for 71,800 shares and 103,000 RSUs.","Bauerlein previously CFO of Inogen (Nasdaq: INGN) for 12 years and co-founded the company in 2001.","Company posted an investor presentation on its website for use with investors and analysts.","Jim Rodberg ceases serving as interim CFO, Treasurer, and Principal Financial and Accounting Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317316,"accession_number":"0000950170-23-007578","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sight Sciences Q4 2022 revenue up 40% YoY to $20.5M; guides 2023 revenue $89-94M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2022 revenue $71.3M (+46% YoY); Surgical Glaucoma $65.6M (+41%), Dry Eye $5.7M (+133%).","Q4 2022 net loss $16.9M ($0.35/share) vs $15.9M loss ($0.34/share) in Q4 2021.","Q4 2022 operating expenses $33.9M, down 10% sequentially from Q3 2022.","OMNI facilities reached 941 and TearCare facilities grew to 1,042 as of Dec 31, 2022.","2023 revenue guidance $89M-$94M, representing 25%-32% growth over 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317315,"accession_number":"0000950170-23-000514","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences reports preliminary Q4 2022 revenue ~$20.5M, up 40% YoY; CFO Selnick steps down, Rodberg interim","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2022 total revenue $20.4M-$20.6M (+40% YoY); full-year revenue $71.2M-$71.4M (+46% YoY).","Surgical Glaucoma revenue Q4 $18.7M-$18.8M (+35% YoY); Dry Eye revenue $1.7M-$1.8M (+130% YoY).","CFO Jesse Selnick stepped down effective Jan 9, 2023; will provide transition consulting. Jim Rodberg appointed interim CFO.","Director Mack Hicks resigned from Board and Audit Committee; Dr. Tamara Fountain appointed to Audit Committee.","Company expects to announce complete Q4 and FY2022 results in March 2023; results are preliminary and subject to audit."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":71331000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335567,"accession_number":"0000950170-22-024461","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sight Sciences Q3 revenue $18.7M (+43% YoY); narrows FY22 guidance to $70-72M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Surgical Glaucoma revenue $17.1M (+37% YoY); Dry Eye revenue $1.6M (+145% YoY).","Net loss $22.2M ($0.46 per share) vs. $17.2M ($0.43) in Q3 2021.","Gross margin 84%; operating expenses $37.6M (+50% YoY).","Full-year 2022 revenue guidance tightened to $70-72M from prior $68-72M.","Launched SION bladeless goniotomy device; completed enrollment for SAHARA dry eye trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":50788000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352989,"accession_number":"0000950170-22-017687","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2022-08-23T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Sight Sciences launches SION bladeless surgical instrument for goniotomy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SION is a manually operated, bladeless device that excises trabecular meshwork tissue using specialized lasers.","Designed to improve safety and ease by eliminating sharp instrumentation in the anterior chamber.","Surgeons reported smooth navigation and tissue removal without getting stuck in scleral back wall.","Expands Sight Sciences' MIGS portfolio alongside OMNI Surgical System, targeting the growing goniotomy subsegment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352988,"accession_number":"0000950170-22-016862","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sight Sciences Q2 revenue $17.2M (+37% YoY); net loss $23.8M; FY22 guidance $68-72M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Surgical Glaucoma revenue $15.9M (+33% YoY); Dry Eye revenue $1.3M (+143% YoY).","Gross margin expanded to 84% from 82% YoY on manufacturing cost reductions.","Operating expenses rose 75% to $37.4M, driven by personnel and R&D investment.","Cash and equivalents $220.1M; total debt $33.0M as of June 30, 2022.","Full-year 2022 revenue guidance: $68-72M, representing 39-47% growth over 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":32111000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":273137905.190965,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-11T23:59:59+00:00|352988"}